OncoMatch/Clinical Trials/NCT06975410
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Is NCT06975410 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies YH32364 for egfr overexpression.
Treatment: YH32364 — This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: EGFR overexpression (ihc3+ or ihc2+) (ihc3+ or ihc2+)
Disease stage
Metastatic disease required
[Dose Escalation Only] Locally advanced or metastatic EGFR overexpressing solid tumor* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available standard therapy
refractory or intolerable on all available standard therapy
Cannot have received: 4-1BB/CD137-modulating agent
Previous treatment with a 4-1BB/CD137-modulating agent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06975410 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior 4-1BB/CD137-modulating agent disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR overexpression (ihc3+ or ihc2+) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify